Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells $69,202.80 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 8,180 shares of the stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $69,202.80. Following the transaction, the insider directly owned 267,274 shares of the company’s stock, valued at $2,261,138.04. This represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mollie Leoni also recently made the following trade(s):

• On Friday, November 14th, Mollie Leoni sold 15,485 shares of Kura Oncology stock. The shares were sold at an average price of $11.18, for a total value of $173,122.30.

Kura Oncology Stock Performance

Shares of KURA stock opened at $8.22 on Friday. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The stock has a 50 day simple moving average of $10.21 and a 200-day simple moving average of $9.04. The company has a market cap of $715.30 million, a price-to-earnings ratio of -3.31 and a beta of 0.25. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $12.49.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The business had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. On average, equities analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Tuesday, January 13th. Zacks Research lowered Kura Oncology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 20th. JMP Securities reaffirmed a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research note on Monday, October 20th. UBS Group lifted their price objective on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Finally, Leerink Partners set a $20.00 target price on Kura Oncology and gave the company an “outperform” rating in a report on Tuesday, January 13th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $28.00.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its holdings in Kura Oncology by 392.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after buying an additional 3,072 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after acquiring an additional 3,769 shares in the last quarter. Merit Financial Group LLC acquired a new stake in shares of Kura Oncology during the third quarter valued at $89,000. Jain Global LLC purchased a new stake in Kura Oncology during the 3rd quarter worth about $91,000. Finally, Lazard Asset Management LLC raised its stake in Kura Oncology by 222.3% in the 3rd quarter. Lazard Asset Management LLC now owns 10,423 shares of the company’s stock valued at $92,000 after purchasing an additional 7,189 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.